Alterity Shares Rise After Phase 2 Multiple System Atrophy Trial Interim Data

MT Newswires Live07-18

Alterity Therapeutics (ATHE) shares rose 13.6% in recent Wednesday trading after the company said preliminary data from a phase 2 trial showed that its investigative drug ATH434 improved symptoms in patients with multiple system atrophy.

Interim data showed that out of seven MSA patients who have completed six months of ATH434 treatment, three had reduced disability and two had stable or improved neurological symptoms, according to Alterity.

The drug was generally well-tolerated with no serious adverse events reported, the company said.

Although the data are preliminary, the company said it sees a "positive trend" with the outcomes.

Price: 2.25, Change: +0.27, Percent Change: +13.64

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2452198968?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-07-18 01:39","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2452198968","market":"us","top_or_hot":-1,"title":"Alterity Shares Rise After Phase 2 Multiple System Atrophy Trial Interim Data","media":"MT Newswires Live","content":"<html><body><p> Alterity <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> (ATHE) shares rose 13.6% in recent Wednesday trading after the company said preliminary data from a phase 2 trial showed that its investigative drug ATH434 improved symptoms in patients with multiple system atrophy.</p><p>Interim data showed that out of seven MSA patients who have completed six months of ATH434 treatment, three had reduced disability and two had stable or improved neurological symptoms, according to Alterity.</p><p>The drug was generally well-tolerated with no serious adverse events reported, the company said.</p><p>Although the data are preliminary, the company said it sees a \"positive trend\" with the outcomes.</p><p>Price: 2.25, Change: +0.27, Percent Change: +13.64</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Alterity Shares Rise After Phase 2 Multiple System Atrophy Trial Interim Data</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAlterity Shares Rise After Phase 2 Multiple System Atrophy Trial Interim Data\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-07-18 01:39 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.mtnewswires.com/><strong>MT Newswires Live</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Alterity Therapeutics (ATHE) shares rose 13.6% in recent Wednesday trading after the company said preliminary data from a phase 2 trial showed that its investigative drug ATH434 improved symptoms in ...</p>\n\n<a href=\"https://www.mtnewswires.com/\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2452198968","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2452198968","pubTimestamp":1721237942,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Alterity Therapeutics  shares rose 13.6% in recent Wednesday trading after the company said preliminary data from a phase 2 trial showed that its investigative drug ATH434 improved symptoms in patients with multiple system atrophy.Interim data showed that out of seven MSA patients who have completed six months of ATH434 treatment, three had reduced disability and two had stable or improved neurological symptoms, according to Alterity.The drug was generally well-tolerated with no serious adverse events reported, the company said.Although the data are preliminary, the company said it sees a \"positive trend\" with the outcomes.Price: 2.25, Change: +0.27, Percent Change: +13.64","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","ATHE":"Alterity Therapeutics Limited"},"translate_title":"Alterity股价在2期多系统萎缩试验中期数据后上涨","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ATHE":0.9},"content_text":"Alterity Therapeutics (ATHE) shares rose 13.6% in recent Wednesday trading after the company said preliminary data from a phase 2 trial showed that its investigative drug ATH434 improved symptoms in patients with multiple system atrophy.Interim data showed that out of seven MSA patients who have completed six months of ATH434 treatment, three had reduced disability and two had stable or improved neurological symptoms, according to Alterity.The drug was generally well-tolerated with no serious adverse events reported, the company said.Although the data are preliminary, the company said it sees a \"positive trend\" with the outcomes.Price: 2.25, Change: +0.27, Percent Change: +13.64","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2452198968"}